
Update Ongoing Trials BS BMT-Unit



Ongoing non-sponsored studies (2020)

Study	WP	Field	Responsible	Pt	Publication	Submitted EC	EC approval
GIMS	REL-Passamonti	LMC	Polverelli	7	Blood res 2020	Yes	13/Nov/2017
MF-2001	MF-Net	MPN	Polverelli	40	BJH 2020; project ongoing	No	/
RUX-MF-DFX	MF-Net	MPN	Polverelli	2	Awaiting	Yes	06/Jul/2017
RUXOREL	REL-Passamonti	MPN	Polverelli	22	Blood Adv2019; ongoing	Yes	30/Jan/2018
PV-real life	PV-Net	MPN	Polverelli	10	awaiting	Yes	28/May/2020
MVs-IN-MPS	MF-Net	MPN	Polverelli	2	awaiting	Yes	22/Jul/2020
PTCy vs ATG in MF	CMWP	2020	Polverelli	11	awaiting	No	/
FT vs FB in MF	CMWP	2020	Polverelli	8	awaiting	No	/

Ongoing non-sponsored studies (2020)

Studies	Submitted EC	EC approval	Enrolled patients	Published abstract	Published full paper
Allogenic SCT in elderly: BS Study	Yes	22/03/2019	50	No	No
OPTkIMA Study 1013	Yes	31/03/2015	26 centers – 220 pt	Yes	Yes
Modulen-TGF-β2	Yes	27/02/2020	40	No	No
MicrobiomAML	Yes	11/Jan/2019	1	No	No
Prospective study on the psycho- social well-being of the pt candidate for HSCT and his caregiver	Yes	Jan/2020	33 (15 \mathfrak{P} ;18 \mathfrak{T}) and 20 caregiver	No	No

Allogenic SCT in elderly: BS Study

Allogenic stem cell transplantation (ALLO-SCT) in elderly: a prospective hematogeriatric joint evaluation – ALLO-ELD study

Type of study:

retrospective observational

Primary objective:

Description of the patients popoulation. This objective will particularly focus on the changing, over the years, of the clinical and hematological characteristics of elderly patients submitted to allo-SCT

PI: Prof Michele Malagola


OPTkIMA Study 1013 - OPtimize **TKI**s **Multiple Approaches**

Phase-III randomized study to Optimize TKIs Multiple Approaches - (OPTkIMA) – and quality of life (QoL) in elderly patients (≥60 years) with Ph+ chronic myeloid leukemia (CML) and MR3.0/MR4.0 stable molecular response

Phase: III

Primary objective:

To investigate whether "progressive" intermittent administration of TKIs (experimental arm) provides better outcomes than "fixed" intermittent administration of TKIs (control arm) in the following QoL scales: Fatigue, Physical Functioning and Global Health Status/QoL (outcome measure: EORTC QLQ-C30), Impact on Daily Life and Symptom Burden (outcome measure: EORTC CML-24), Burden of Illness (outcome measure: EORTC QLQ-ELD14).



PI: Prof Domenico Russo

OPTkIMA Study 1013 - OPtimize **TKI**s **Multiple Approaches**

632. CHRONIC MYELOID LEUKEMIA: THERAPY: POSTER III | NOVEMBER 29, 2018

First Interim Report of the Italian Multicentric Phase-III Randomized Study to
Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable
Molecular Response

Michele Malagola, MD, Fabio Efficace, PhD, Nicola Polverelli, MD, Elisabetta Abruzzese, Alessandra Iurlo, Cristina Bucelli, MD, Fabio Stagno, Massimiliano Bonifacio, Mariella D'adda, MD, Monia Lunghi, Monica Crugnola, MD, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Ferrari Maria Luisa, Micaela Bergamaschi, MD, Gianni Binotto, MD, Rosaria Sancetta, MD, Maria Rosaria Coppi, Valentina Giai, Giovanna Rege Cambrin, MD, Atelda Romano, Mario Tiribelli, Sabina Russo, Lara Aprile, Antonietta Pia Falcone, MD, Serena Rupoli, MD, Antonella Russo Rossi, MD, Emilio Usala, MD, Bruno Martino, MD, Lisa Gandolfi, Simona Bernardi, PhD, Camilla Zanaglio, PhD, Mirko Farina, MD, Michele Baccarani, MD, Domenico Russo, MD

```
Realed 9 August 200 | Realed 10 October 200 | Accepted 20 January 2001
DOI:10.1002/baseA3776

ORIGINAL RESEARCH

Cancer Medicine
WILEY
```

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study

¹Unit of Binoil Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST-Spoilati Civili, Brescia, Italy

³Hernatology Division, Foundation IRCCS Ca, Granda Ospedale Maggiore Policiteico, Milan, Italy

³Division of Hematology, S. Eugenio Hospital, ASL ROMA2, Tor Vergata University, Roma, Italy

Department of Modicine, Section of Hernatology, University of Verona, Verona, I taly

*Department of Hematology, University of Catanta, Catanta, Italy

"Hematology and Citrical Immunology, Department of Modicine, Parkus School of Modicine, Parkus, Italy

³Division of Hematology, ASST-Speciali Civili di Beneta, Brencia, Italy

*Division of Hematology, Dengriment of Translation Medicine, University of Eastern Pandmont, Newara, Italy

*Homatology Unit and BMT Center Axionda Ospedations Universitaria Parma, Parma, Italy

The materiogy and Bone Marrow Transplant Unit, ASST Papa Grovanet XXIII, Bergamo, Italy

"He materiogy and Bone Marrow Transplantation (BMT) Unit, San Raffacte Scientific Institute, Milan, Italy

**He matering Unit, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpight Unitersity Hospital, University of Roberts, Reference, Balty

DECCS Intitute Remagnetic per le Stadio del Turneri (RST) "Dise A maderi", Meldela, llaby

¹⁶Clinic of Hematology, University of Geneu, Oversials Policitrics S. Martine, IRCCS, Geneu, Italy

15 He materiogy Unit, DelfA nacto Hoonital, Venezia-Mestro, Italy

"Harmatology and BMT Unit "Antonio Porrino" Hospital, Brindisi, Italy

"He matelogy Division, Azienda Osmolallera Santi Antonio e Biagio e Ce sam Arrigo, Ale soundria, Italy

¹⁹Mo dicina Interna a Indintesso Ematologico, O spedate San Latgi, Orbanano, Italy

PERCES Regina Farna National Cancer Institute-Rome, Roma, Italy

**Division of Hematology and BMT, Department of Medical and Morphological Researches, University of Usine, Usine, Italy

21 He materiogy and Transplants Unit, University of Bart, Bart, Italy

"Division of Hemaniciogy, Dipartimento di Patologia Umana dell'Adulto e dell'Adulto e dell'Età Evolutiva, Policimico G Martino, University of Micetra, Meceina, Italy

This is no open screen article under the terms of the Containe Commons. A tribution License, which permits use, distribution and reproduction in say must un, provided the original work in properly clear.

© 2021 The Authorn, Concer Medicine published by John Wiley & Sonof, id.

Const Medicine. 2021;90:1-12. wik-yerlinelibrary.com/journal/const 1

Modulen – TGF-β2

Nutritional support with TGF-β2 enriched polymeric formulation in patients undergoing haematopoietic stem cell transplantation (HSCT)

Type of study:

Interventional perspective

Primary objective:

Evaluation of clinical and nutrizional impact of taking the formulation enriched with TGF-β2 on the incidence of malnutrition at +28 days after transplantation in patient undergoing allo-SCT

PI: Dr Enrico Morello


Prospective study on the psycho-social well-being of the pt candidate for HSCT and his caregiver

Type of study:

Prospective

Primary objective:

Dynamic detection of psychological distress through a systemic screening of the emotional distress and unexpressed needs of patients who are candidate for HSCT, wich allows the identification of all patients who need to be a psychological interventions and expansion of the transplant guide



PI: Dr Elsa Cavagna

MicrobiomAML

Prospective biological, non pharmacological, no-profit study for NGS evaluation of microbiome in Acute Myeloid Leukemia patients from diagnosis to one month after allogenic Stem Cell Transplantation

Type of study:

Prospective

Primary objective:

Evaluate by NGS the microbiota of AML patients from diagnosis to allo-SCT



PI: Dr Enrico Morello